The amyloid PET agent F-18 flutemetamol (Vizamyl) was the topic of two scientific sessions at the Alzheimer’s Association International Conference (AAIC), which concluded yesterday in Copenhagen. Results of one study showed how patients with mild cognitive impairment (MCI) whose scans were positive for flutemetamol were 2.5 times more likely to progress to Alzheimer’s disease. Another study of early onset dementia patients showed improvements in clinical decision making and clinician confidence as a result of information gleaned from flutemetamol PET. {read more here}